OPKO Health Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Total revenue for Q3 2025 was $151.6 million, down from $193.7 million in Q3 2024. This includes $95.2 million from the Diagnostics segment and $56.4 million from Pharmaceuticals.

Diagnostics Revenue: $95.2 million, including $19.5 million from sold oncology assets. Excluding these assets, revenue increased by approximately 20% driven by the 4Kscore test.

Pharmaceutical Revenue: $56.4 million, an 8% increase year-over-year. Rayaldee contributed $7.5 million, a 29% increase from the previous year.

Net Income: $21.6 million, or $0.03 per share, compared to $24.9 million in Q3 2024.

Cash Position: Ended the quarter with over $428 million in cash and equivalents, supporting ongoing operations and stock repurchase programs.

2Strategic Updates and Business Highlights

Sale of BioReference Health's Oncology Division: Completed in September 2025 for $192.5 million, streamlining operations and focusing on core clinical testing and the 4Kscore test.

4Kscore Test Expansion: FDA label expansion allows use without a digital rectal exam, expected to significantly increase market adoption among primary care physicians.

Partnership with Regeneron: A collaboration to develop multispecific antibodies using ModeX's MSTAR platform, with potential milestone payments exceeding $1 billion.

Pipeline Advancements: Multiple candidates in clinical trials, including MDX2001 (immuno-oncology), MDX2004 (immune rejuvenator), and an EBV vaccine in partnership with Merck.

3Forward Guidance and Outlook

Q4 2025 Revenue Guidance: Expected between $135 million and $140 million, with Diagnostics services revenue of $70 million to $75 million.

2026 Outlook: Anticipates BioReference to achieve profitability with low single-digit revenue growth. Pharmaceutical businesses, including Rayaldee, expected to grow in the mid-single-digit percentages.

R&D Investment: Plans to invest up to $100 million in R&D programs, with up to 6 Phase I programs enrolling in 2026.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Overall revenue decreased due to the sale of oncology assets, affecting year-over-year comparisons.

Pharmaceutical Sales Pressure: Lower sales in Chile and foreign currency headwinds impacted product revenue.

Market Conversion Delays: Slow conversion rates in the long-acting market have led to conservative profit share guidance from Pfizer, which may affect future revenue expectations.

5Notable Q&A Insights

MDX2001 Development: Currently at the fifth dose level with five patients dosed; expansion cohorts will focus on tumor types with high CMet and Trop2 expression.

4Kscore Growth: The recent 20% growth is attributed to existing demand, with expectations for further acceleration due to the new label.

Regeneron Collaboration: The partnership is not limited to oncology; it includes programs in metabolism and immunology, with preclinical and clinical milestones expected.

EBV Vaccine Data Reporting: Anticipated to be reported by Merck, with a focus on select populations at risk for EBV-related infections. This summary encapsulates OPKO Health's financial performance, strategic initiatives, future outlook, and key concerns while highlighting insights from the Q&A session.